URALCHEM and the Ziedot.lv Fund present New Year Gifts to seriously ill children in Latvia

Riga, Latvia - December 20, 2012 -- URALCHEM and a leading Latvian charity organization, the Ziedot.lv Fund, held New Year activities and events for a group of seriously ill children in Latvia and members of their families. URALCHEM's CEO, Dmitry Konyaev, and the head of the Ziedot.lv Fund, Ruta Dimanta, gave presents to the children. These children are beneficiaries of a joint charity programme "Help for seriously ill children", which was launched in the autumn of this year.

In September 2012, URALCHEM and the Ziedot.lv Fund signed an agreement that started a charitable programme for the treatment of 20 children from Latvia in leading Russian clinics. URALCHEM is providing total funding to the amount of €80 thousand.

Since the launch of the programme, 11 families have received help with specific treatment or rehabilitation for their children using leading Russian clinics. The Ziedot.lv Fund has selected clinics and treatment programmes on the basis of doctors' recommendations and requests from parents for financial assistance. URALCHEM has currently provided €25 thousand of funding.

Dmitry Konyaev came to Latvia to show his support for the children and give them New Year presents. "We are pleased that the company's social policy in Latvia is generating results already. Together with the Ziedot.lv Fund, we intend to continue our support for the children. They are now on their way to recovery and I wish them success in the coming year in overcoming their problems," he said.

Ruta Dimanta said that the Fund treated every case individually, choosing leading medical institutions in Russia to carry out the treatments. In clinical cases involving children with rare or complex conditions requiring care outside Latvia and not funded by the state, URALCHEM's participation enables the provision of hospital and other treatment and support for the children's' families. She added, "The condition of the children who have been helped has improved significantly. We are grateful to the Russian doctors and to URALCHEM for their assistance. Our joint programme is gaining momentum and I hope that as a result, next year more families will be able to celebrate this holiday with joy."

-Ends-

Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of URALCHEM. We wish to caution you that these statements are only predictions. We do not intend to update these statements and our actual results may differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, financial risk management and the impact of general business and global economic conditions.

URALCHEM, OJSC is one of the largest producers of nitrogen and phosphate fertilisers in Russia and the CIS with production capacities of over 2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is the second largest ammonium nitrate producer in the world and number one in Russia, the second largest producer of nitrogen fertilisers in Russia. Key production assets of URALCHEM, OJSC include Azot Branch of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm; MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk, Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk, Moscow region.

Media Contact:
Public Relations Department
URALCHEM, OJSC
10, Presnenskaya Naberezhnaya
Moscow, Russian Federation, 123317
Tel: +7 (495) 721 89 89
E-Mail: pr@URALCHEM.com
Web: http://www.uralchem.com

This release was published on openPR.